By synergizing with HMGB1, released from dying tumor cells and signaling through toll-like receptor (TLR) 4, activated DC are licensed to prime an anti-tumor immune response in a caspase-1- and IL-1β-dependent manner. This evidence concerns the gene HMGB1 and neoplasm.